LSP Life Sciences Fund

Monthly Report April 2015

Performance

YTD	1 Month	3 Months	1 Year	2 Years	3 Years	
10.1%	-0.3%	2.2%	37.3%	78.1%	106.1%	
Top-5 pe	rformers					
1. Lombard Medical			14.1%			
2. Clinigen Group			12.3%			
3. Enanta Pharmaceuticals			11.8%			
4. Ablynx			8.7%			
5. Forward Pharma			8.1%			


IU	CONNECTING INVESTORS TO INVENTORS		
NAV per Sł	hare € 202.79		
NAV of Fund	75,325,024		
Number of Shares	371,428		
Valuation Date	30/04/2015		
Inception date:	27/04/2011		
Currency:	Euro		
Domicile:	The Netherlands		
Legal Structure:	Dutch NV with variable capital		
Listing:	Euronext Amsterdam		
Euronext code:	LSP		
ISIN Code:	NL0009756394		
Bloomberg:	LSP NA		

Investment strategy

The Fund's primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical-, specialist pharmaceutical-, medical device-, drug delivery-, vaccineand diagnostic companies). The majority of the Fund's portfolio will consist of European companies listed on one of the (main) European stock exchanges, with a market capitalization of below $\in 1$ billion at the time of investment.

Manager's comments

The April markets proved turbulent but the Fund performance remained almost flat on the previous month. One of the most exciting portfolio events of the month was the announcement that portfolio company, Clinigen, had made a bold and strategically compelling move to acquire its largest competitor, Idis, for GBP225 million. This makes Clinigen the number one player in the global ethical unlicensed supply market. Analysts estimate that this largely unpenetrated market could have a value in excess of \$5 billion. Clinigen funded the deal though a mix of equity and debt - raising GBP 135 million in an oversubscribed offering. Recent portfolio addition, Cardio 3 Biosciences – renamed the company Celyad and announced its ambition to list on NASDAQ in conjunction with an equity offering. The name change reflects the recent acquisition of cutting edge immune-oncology technology and assets giving the company both a late stage cardiovascular asset and early stage oncology programs. This month, we added Circassia to the portfolio. This UK company has a unique approach to the treatment of allergies – a growing problem worldwide and for which there are few treatment options. If successful, Circassia's technology could dramatically improve patients' immune response to allergens. The lead program to treat cat allergy is in phase III testing.



Important information

LSP Advisory B.V. (as Fund Manager) and the LSP Life Sciences Fund N.V. (the Fund) have a license and are registered pursuant to the Dutch Act on Financial Supervision and are supervised by the Stichting Autoriteit Financiële Markten (Dutch Authority for the Financial Markets) and De Nederlandsche Bank N.V. (the Dutch Central Bank). This presentation is solely for information purposes and is not intended as advice in any way. The Fund Manager and the Fund cannot be held liable or responsible for the content of this presentation. Potential investors are advised to contact their investment-and fiscal advisor prior to taking an investment decision. There are risks involved in the investment. The value of the investment can fluctuate. Results achieved in the past offer no guarantee for the future. A Key Investor Information Document is also available for this product with information about the product, the costs and the risks involved. Read it before you invest in the product. The prospectus and the Key Investor Information Document of the LSP Life Sciences Fund can be downloaded via www.lspvc.com/funds/public.html

LSP Life Sciences Fund



Portfolio breakdown

Company	Stage	Subsector	Marketcap	%
Ablynx	Early	Therapeutics	Small	6.9%
Circassia Pharmaceuticals	Late	Therapeutics	Small	6.8%
Enanta Pharmaceuticals	Market	Therapeutics	Small	6.7%
Clinigen Group	Market	Specialty Pharma	Small	6.4%
ProQR Therapeutics	Early	Therapeutics	Small	6.1%
Neurocrine Biosciences	Late	Therapeutics	Mid	6.1%
Cempra	Late	Therapeutics	Mid	6.0%
Genmab	Market	Therapeutics	Mid	5.9%
Forward Pharma	Late	Therapeutics	Mid	5.4%
Ascendis Pharma	Early	Therapeutics	Small	5.0%
Lombard Medical	Market	Medical Device	Micro	4.5%
PTC Therapeutics	Market	Therapeutics	Mid	4.2%
Sphere Medical	Market	Medical Device	Micro	4.0%
Egalet	Market	Specialty Pharma	Small	3.3%
Galapagos	Early	Therapeutics	Mid	3.0%
AcelRx	Late	Medical Device	Small	2.5%
Zealand Pharma	Market	Therapeutics	Small	2.3%
Nordic Nanovector	Early	Therapeutics	Small	2.1%
Celyad	Late	Therapeutics	Small	1.8%
Cellectis	Early	Therapeutics	Small	0.0%